Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports

13-10-2016 | Bone and Diabetes (A Schwartz and P Vestergaard, Section Editors)

Vitamin D Level Between Calcium-Phosphorus Homeostasis and Immune System: New Perspective in Osteoporosis

Authors: Daniele Bellavia, Viviana Costa, Angela De Luca, Melania Maglio, Stefania Pagani, Milena Fini, Gianluca Giavaresi

Published in: Current Osteoporosis Reports

Login to get access

Abstract

Vitamin D is a key molecule in calcium and phosphate homeostasis; however, increasing evidence has recently shown that it also plays a crucial role in the immune system, both innate and adaptive. A deregulation of vitamin D levels, due also to mutations and polymorphisms in the genes of the vitamin D pathway, determines severe alterations in the homeostasis of the organism, resulting in a higher risk of onset of some diseases, including osteoporosis. This review gives an overview of the influence of vitamin D levels on the pathogenesis of osteoporosis, between bone homeostasis and immune system.
Appendix
Available only for authorised users
Literature
1.
Bonjour P, Clark P, Cooper C, Dawson-Hughes B, De Laet C, Delmas P, et al. WHO scientific group on the assessment of osteoporosis at primary health care level. Summary meeting report. 2004. Brussels, Belgium, 5–7 May 2004.
2.
Van den Bergh JP, van Geel TA, Geusens PP. Osteoporosis, frailty and fracture: implications for case finding and therapy. Nat Rev Rheumatol. 2012;8:163–72.PubMedCrossRef
3.
Fini M, Salamanna F, Veronesi F, Torricelli P, Nicolini A, Benedicenti S, et al. Role of obesity, alcohol and smoking on bone health. Front Biosci (Elite Ed). 2012;4:2686–706.
4.
Engelke K, Gluer CC. Quality and performance measures in bone densitometry. I. Errors and diagnosis. Osteoporos Int. 2006;17:1283–92.PubMedCrossRef
5.
Gluer CC, Lu Y, Engelke K. Quality and performance measures in bone densitometry. II. Fracture risk. Osteoporos Int. 2006;17:1449–58.PubMedCrossRef
6.
Blake GM, Fogelman I. Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis. J Clin Densitom. 2007;10:102–10.PubMedCrossRef
7.
Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24:23–57.PubMedCrossRef
8.
Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. National osteoporosis foundation. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25:2359–81.PubMedPubMedCentralCrossRef
9.
Lentle B, Cheung AM, Hanley DA, Leslie WD, Lyons D, Papaioannou A, et al. Scientific Advisory Council of Osteoporosis Canada. Osteoporosis Canada 2010 guidelines for the assessment of fracture risk. Can Assoc Radiol J. 2011;62:243–50.PubMedCrossRef
10.
Lau EMC, Sambrook P, Seeman E, Leong KH, Leung PC, Delmas P. Guidelines for diagnosing, prevention and treatment of osteoporosis in Asia. APLAR J Rheumatol. 2006;9:24–36.CrossRef
11.
Al-Saleh Y, Sulimani R, Sabico S, Raef H, Fouda M, Alshahrani F, et al. Guidelines for osteoporosis in Saudi Arabia: recommendations from the Saudi Osteoporosis Society. Ann Saudi Med. 2015;35:1–12.PubMed
12.
Maalouf G, Gannagé-Yared MH, Ezzedine J, Larijani B, Badawi S, Rached A, et al. Middle East and North Africa consensus on osteoporosis. J Musculoskelet Neuronal Interact. 2007;7:131–43.PubMed
13.
Pecina JL, Romanovsky L, Merry SP, Kennel KA, Thacher TD. Comparison of clinical risk tools for predicting osteoporosis in women ages 50–64. J Am Board Fam Med. 2016;29:233–9.PubMedCrossRef
14.
Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 2000;11:S2–S17.PubMedCrossRef
15.
Johnell O, Oden A, De Laet C, Garnero P, Delmas PD, Kanis JA. Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int. 2002;13:523–6.PubMedCrossRef
16.
Adami S, Bertoldo F, Brandi ML, Cepollaro C, Filipponi P, Fiore E, et al. Società Italiana dell’Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro. Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo. 2009;61:260–84.PubMed
17.
18.
Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster JY. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int. 2005;76:176–86.PubMedCrossRef
19.
Ström O, Borgstrom F, Kanis JA, Compston JE, Cooper C, McCloskey E, et al. Osteoporosis: burden, health care provision and opportunities in the EU. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2011;6:59–155. doi:10.​1007/​s11657-011-0060-1.PubMedCrossRef
20.
Weaver CM, Alexander DD, Boushey CJ, Dawson-Hughes B, Lappe JM, LeBoff MS, et al. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int. 2016;27:367–76.PubMedCrossRef
21.
Brannon PM, Yetley EA, Bailey RL, Picciano MF. Vitamin D and health in the 21st century: an update. Am J Clin Nutr. 2008;88:483S–90S.PubMed
22.
23.
24.
Mathieu C, Badenhoop K. Vitamin D and type 1 diabetes mellitus: state of the art. Trends Endocrinol Metab. 2005;16:261–6.PubMedCrossRef
25.
Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med. 2008;358:2355–65.PubMedCrossRef
26.
Holick MF, MacLaughlin JA, Clark MB, Holick SA, Potts JT. Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science. 1980;210:203–5.PubMedCrossRef
27.
Mac Laughlin JA, Anderson RR, Holick MF. Spectral character of sunlight modulates photosynthesis of previtamin D3 and its photoisomers in human skin. Science. 1982;216:1001–3.CrossRef
28.
29.
Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci. 2004;29:664–73.PubMedCrossRef
30.
Ohyama Y, Yamasaki T. Eight cytochrome P450S catalyze vitamin D metabolism. Front Biosci. 2005;10:608–19.CrossRef
31.
Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88:582S–6S.PubMed
32.
33.
34.
35.
Henry HL. The 25(OH)D3/1α,25(OH)2D3-24R-hydroxylase: a catabolic or biosynthetic enzyme? Steroids. 2001;66:391–8.PubMedCrossRef
36.
Henry HL. Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab. 2011;25:531–41.PubMedCrossRef
37.
Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr. 2004;80:1717S–20S.PubMed
38.
Chen J, Lobachev KS, Grindel BJ, Farach-Carson MC, Hyzy SL, El-Baradie KB, et al. Chaperone properties of pdia3 participate in rapid membrane actions of 1α,25-dihydroxyvitamin D3. Mol Endocrinol. 2013;27:1065–77.PubMedCrossRef
39.
Holick MF, Schnoes HK, DeLuca HF, Gray RW, Boyle IT, Suda T. Isolation and identification of 24,25-dihydroxycholecalciferol, a metabolite of vitamin D made in the kidney. Biochemistry. 1972;11:4251–5.PubMedCrossRef
40.
Kumar R, Schnoes HK, DeLuca HF. Rat intestinal 25-hydroxyvitamin D3- and 1α,25-dihydroxyvitamin D3-24-hydroxylase. J Biol Chem. 1978;253:3804–9.PubMed
41.
Halloran BP, Castro ME. Vitamin D kinetics in vivo: effect of 1, 25-dihydroxyvitamin D administration. Am J Physiol. 1989;256:E686–91.PubMed
42.
Clements MR, Davies M, Hayes ME, Hickey CD, Lumb GA, Mawer EB, et al. The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol. 1992;37:17–27.CrossRef
43.
Akeno N, Saikatsu S, Kimura S, Horiuchi N. Induction of vitamin D 24-hydroxylase messenger RNA and activity by 22-oxacalcitriol in mouse kidney and duodenum. Possible role in decrease of plasma 1α,25-dihydroxyvitamin D3. Biochem Pharmacol. 1994;48:2081–90.PubMedCrossRef
44.
Demay MB, Gerardi JM, DeLuca HF, Kronenberg HM. DNA sequences in the rat osteocalcin gene that bind the 1,25-dihydroxyvitamin D3 receptor and confer responsiveness to 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A. 1990;87:369–73.PubMedPubMedCentralCrossRef
45.
Holick MF. Vitamin D, status: measurement, interpretation, and clinical application. Ann Epidemiol. 2009;19:73–8.PubMedCrossRef
46.
Zierold C, Darwish HM, DeLuca HF. Identification of a vitamin D-response element in the rat calcidiol (25-hydroxyvitamin D3) 24-hydroxylase gene. Proc Natl Acad Sci U S A. 1994;91:900–2.PubMedPubMedCentralCrossRef
47.
Zierold C, Darwish HM, DeLuca HF. Two vitamin D response elements function in the rat 1,25-dihydroxyvitamin D 24-hydroxylase promoter. J Biol Chem. 1995;270:1675–8.PubMedCrossRef
48.
Darwish HM, DeLuca HF. Recent advances in the molecular biology of vitamin D action. Prog Nucleic Acid Res Mol Biol. 1996;53:321–44.PubMedCrossRef
49.
Ozono K, Liao J, Kerner SA, Scott RA, Pike JW. The vitamin D-responsive element in the human osteocalcin gene. Association with a nuclear proto-oncogene enhancer. J Biol Chem. 1990;265:21881–8.PubMed
50.
Nishikawa J, Matsumoto M, Sakoda K, Kitaura M, Imagawa M, Nishihara T. Vitamin D receptor zinc finger region binds to a direct repeat as a dimer and discriminates the spacing number between each half-site. J Biol Chem. 1993;268:19739–43.PubMed
51.
Kim MS, Fujiki R, Kitagawa H, Kato S. 1alpha,25(OH)2D3-induced DNA methylation suppresses the human CYP27B1 gene. Mol Cell Endocrinol. 2007;265–266:168–73.PubMedCrossRef
52.
Kim MS, Fujiki R, Murayama A, Kitagawa H, Yamaoka K, Yamamoto Y, et al. 1Alpha,25(OH)2D3-induced transrepression by vitamin D receptor through E-box-type elements in the human parathyroid hormone gene promoter. Mol Endocrinol. 2007;21:334–42.PubMedCrossRef
53.
Kitazawa S, Kajimoto K, Kondo T, Kitazawa R. Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. J Cell Biochem. 2003;89:771–7.PubMedCrossRef
54.
Jones G, DeLuca HF. HPLC of vitamin D and its metabolites. In: Makin HLJ, Newton R, editors. High performance liquid chromatography and its application to endocrinology, Monographs on endocrinology, vol. 30. Berlin: Springer; 1988. p. 95–139.CrossRef
55.
Brown EM, Pollak M, Hebert SC. The extracellular calcium-sensing receptor: its role in health and disease. Annu Rev Med. 1998;49:15–29.PubMedCrossRef
56.
Jones G, Strugnell S, De Luca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev. 1998;78:1193–231.PubMed
57.
58.
Suda T, Ueno K, Fujii K, Shinki T. Vitamin D and bone. J Cell Biochem. 2003;88:2259–66.CrossRef
59.
Redmond J, Jarjou LM, Zhou B, Prentice A, Schoenmakers I. Ethnic differences in calcium, phosphate and bone metabolism. Proc Nutr Soc. 2014;73:340–51.PubMedPubMedCentralCrossRef
60.
Kinyamu HK, Gallagher JC, Prahl JM, DeLuca HF, Petranick KM, Lanspa SJ. Association between intestinal vitamin D receptor, calcium absorption, and serum 1,25-dihydroxyvitamin D in normal young and elderly women. J Bone Miner Res. 1997;12:922–8.PubMedCrossRef
61.
Levine BS, Singer FR, Bryce GF, Mallon JP, Miller ON, Coburn JW. Pharmacokinetics and biologic effects of calcitriol in normal humans. J Lab Clin Med. 1985;105:239–46.PubMed
62.
63.
64.
Loi F, Córdova LA, Pajarinen J, Lin TH, Yao Z, Goodman SB. Inflammation, fracture and bone repair. Bone. 2016;86:119–30.PubMedCrossRef
65.
Rigby WF, Waugh MG. Decreased accessory cell function and costimulatory activity by 1,25-dihydroxyvitamin D3-treated monocytes. Arthritis Rheum. 1992;35:110–9.PubMedCrossRef
66.
Adorini L, Penna G, Giarratana N, Uskokovic M. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J Cell Biochem. 2003;88:227–33.PubMedCrossRef
67.
68.
Lemire JM, Adams JS, Sakai R, Jordan SC. 1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest. 1984;74:657–61.PubMedPubMedCentralCrossRef
69.
Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol. 2007;179:1634–47.PubMedCrossRef
70.
Lemire JMM, Archer DC, Beck L, Spiegelberg HL. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr. 1995;125:1704S–8S.PubMed
71.
Giulietti A, Gysemans C, Stoffels K, van Etten E, Decallonne B, Overbergh L, et al. Vitamin D deficiency in early life accelerates type 1 diabetes in non-obese diabetic mice. Diabetologia. 2004;47:451–62.PubMedCrossRef
72.
Cantorna MT. Mechanisms underlying the effect of vitamin D on the immune system. Proc Nutr Soc. 2011;69:286–9.CrossRef
73.
Baeke F, Korf H, Overbergh L, Verstuyf A, Thorrez L, van Lommel L, et al. The vitamin D analog, TX527, promotes a human CD4+ CD25high CD127low regulatory T cell profile and induces a migratory signature specific for homing to sites of inflammation. J Immunol. 2011;186:132–42.PubMedCrossRef
74.
Palmer MT, Lee YK, Maynard CL, Oliver JR, Bikle DD, Jetten AM, et al. Lineage-specific effects of 1,25-dihydroxyvitamin D3 on the development of effector CD4 T cells. J Biol Chem. 2011;286:997–1004.PubMedCrossRef
75.
Van Belle TL, Gysemans C, Mathieu C. Vitamin D in autoimmune, infectious and allergic diseases: a vital player? Best Pract Res Clin Endocrinol Metab. 2011;25:617–32.PubMedCrossRef
76.
Talaat RM, Mohamed SF, Bassyouni IH, Raouf AA. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity. Cytokine. 2015;72:146–53.PubMedCrossRef
77.
Jeffery LE, Burke F, Mura M, Zheng Y, Qureshi OS, Hewison M, et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol. 2009;183:5458–67.PubMedPubMedCentralCrossRef
78.
Joshi S, Pantalena L, Liu XK, Sarah L, Liu H, Rohowsky-kochan C, et al. 1,25-Dihydroxyvitamin D3 ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol. 2011;31:3653–69.PubMedPubMedCentralCrossRef
79.
Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, Sanvito F, et al. Diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol. 2006;177:8504–11.PubMedCrossRef
80.
Penna G, Amuchastegui S, Giarratana N, Daniel KC, Vulcano M, Sozzani S, et al. 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol. 2007;178:145–53.PubMedCrossRef
81.
82.
Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. Curr Opin Pharmacol. 2010;10:482–96.PubMedCrossRef
83.
Ferreira GB, van Etten E, Verstuyf A, Waer M, Overbergh L, Gysemans C, et al. 1,25-Dihydroxyvitamin D3 alters murine dendritic cell behaviour in vitro and in vivo. Diabetes Metab Res Rev. 2011;27:933–41.PubMedCrossRef
84.
Müller K, Diamant M, Bendtzen K. Inhibition of production and function of interleukin-6 by 1,25-dihydroxyvitamin D3. Immunol Lett. 1991;28:115–20.PubMedCrossRef
85.
Matheu V, Back O, Mondoc E, Issazadeh-Navikas S. Dual effects of vitamin D-induced alteration of TH1/TH2 cytokine expression: enhancing IgE production and decreasing airway eosinophilia in murine allergic airway disease. J Allergy Clin Immunol. 2003;112:585–92.PubMedCrossRef
86.
87.
Wang T, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173:2909–12.PubMedCrossRef
88.
Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005;19:1067–77.PubMedCrossRef
89.
White JH. Vitamin D, metabolism and signaling in the immune system. Rev Endocr Metab Disord. 2012;13:21–9.PubMedCrossRef
90.
Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770–3.PubMedCrossRef
91.
Edfeldt K, Liu PT, Chun R, Fabri M, Schenk M, Wheelwright M, et al. T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. Proc Natl Acad Sci U S A. 2010;107:22593–8.PubMedPubMedCentralCrossRef
92.
Boyce BF, Xiu Y, Li J, Xing L, Yao Z. NF-kB-mediated regulation of osteoclastogenesis. Endocrinol Metab. 2015;30:35–44.CrossRef
93.
Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med. 2004;116:634–9.PubMedCrossRef
94.
Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int. 2005;16:713–6.PubMedCrossRef
95.
Stone K, Bauer DC, Black DM, Sklarin P, Ensrud KE, Cummings SR. Hormonal predictors of bone loss in elderly women: a prospective study. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1998;13:1167–74.PubMedCrossRef
96.
Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168:1174–80.PubMedPubMedCentralCrossRef
97.
Melamed ML, Michos ED, Post W, Astor B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168:1629–37.PubMedPubMedCentralCrossRef
98.
Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168:1340–9.PubMedCrossRef
99.
Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117:503–11.PubMedCrossRef
100.
Looker AC, Mussolino ME. Serum 25-hydroxyvitamin D and hip fracture risk in older US white adults. J Bone Miner Res. 2008;23:143–50.PubMedCrossRef
101.
De Boer IH, Kestenbaum B, Shoben AB, Michos ED, Sarnak MJ, Siscovick DS. 25-Hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol. 2009;20:1805–12.PubMedPubMedCentralCrossRef
102.
Cauley JA, Lacroix AZ, Wu L, Horwitz M, Danielson ME, Bauer DC, et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med. 2008;149:242–50.PubMedPubMedCentralCrossRef
103.
104.
De Boer IH, Levin GP, Robinson-Cohen C, Biggs ML, Hoofnagle AN, Siscovick DS, et al. Serum 25-hydroxyvitamin D concentration and risk for major clinical disease events in a community based population of older adults: a cohort study. Ann Intern Med. 2012;156:627–34.PubMedPubMedCentralCrossRef
105.
Buehring B, Viswanathan R, Binkley N, Busse W. Glucocorticoid-induced osteoporosis: an update on effects and management. J Allergy Clin Immunol. 2013;132:1019–30.PubMedCrossRef
106.
Adachi JD, Olszynski WP, Hanley DA, Hodsman AB, Kendler DL, Siminoski KG, et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum. 2000;29:228–51.PubMedCrossRef
107.
108.
Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98–107.PubMedCrossRef
109.
Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology. 1986;119:84–90.PubMedCrossRef
110.
Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science. 1980;209:823–5.PubMedCrossRef
111.
Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79:820–5.PubMed
112.
113.
114.
García-Hernández A, Arzate H, Gil-Chavarría I, Rojo R, Moreno-Fierros L. High glucose concentrations alter the biomineralization process in human osteoblastic cells. Bone. 2012;50:276–88.PubMedCrossRef
115.
Al-Shoumer KA, Al-Essa TM. Is there a relationship between vitamin D with insulin resistance and diabetes mellitus? World J Diabetes. 2015;6:1057–64.PubMedPubMedCentralCrossRef
116.
Flores M. A role of vitamin D in low-intensity chronic inflammation and insulin resistance in type 2 diabetes mellitus? Nutr Res Rev. 2005;18:175–82.PubMedCrossRef
117.
de Courten B, Mousa A, Naderpoor N, Teede H, de Courten MP, Scragg R. Vitamin D supplementation for the prevention of type 2 diabetes in overweight adults: study protocol for a randomized controlled trial. Trials. 2015;16:335.PubMedPubMedCentralCrossRef
118.
Sarkar M, Bhardwaj R, Madabhavi I, Khatana J. Osteoporosis in chronic obstructive pulmonary disease. Clin Med Insights Circ Respir Pulm Med. 2015;9:5–21.PubMedPubMedCentral
119.
Black PN, Scragg R. Relationship between serum 25-hydroxyvitamin D and pulmonary function in the Third National Health and Nutrition Examination Survey. Chest. 2005;128:3792–8.PubMedCrossRef
120.
Heulens N, Korf H, Janssens W. Innate immune modulation in chronic obstructive pulmonary disease: moving closer toward vitamin D therapy. J Pharmacol Exp Ther. 2015;353:360–8.PubMedCrossRef
121.
Romme EA, Rutten EP, Smeenk FW, Spruit MA, Menheere PP, Wouters EF. Vitamin D status is associated with bone mineral density and functional exercise capacity in patients with chronic obstructive pulmonary disease. Ann Med. 2013;45:91–6.PubMedCrossRef
122.
Heidari B, Javadian Y, Monadi M, Dankob Y, Firouzjahi A. Vitamin D status and distribution in patients with chronic obstructive pulmonary disease versus healthy controls. Caspian J Intern Med. 2015;6:93–7.PubMedPubMedCentral
123.
Sutherland ER, Goleva E, Jackson LP, Stevens AD, Leung DY. Vitamin D levels, lung function and steroid response in adult asthma. Am J Respir Crit Care Med. 2010;181:699–704.PubMedPubMedCentralCrossRef
124.
125.
Hong Q, Xu J, Xu S, Lian L, Zhang M, Ding C. Associations between serum 25-hydroxyvitamin D and disease activity, inflammatory cytokines and bone loss in patients with rheumatoid arthritis. Rheumatology (Oxford). 2014;53:1994–2001.CrossRef
126.
Hoes JN, Bultink IE, Lems WF. Management of osteoporosis in rheumatoid arthritis patients. Expert Opin Pharmacother. 2015;16:559–71.PubMedCrossRef
127.
Varenna M, Manara M, Cantatore FP, Del Puente A, Di Munno O, Malavolta N, et al. Determinants and effects of vitamin D supplementation on serum 25-hydroxy-vitamin D levels in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2012;30:714–9.PubMed
128.
129.
Cai G, Wang L, Fan D, Xin L, Liu L, Hu Y, et al. Vitamin D in ankylosing spondylitis: review and meta-analysis. Clin Chim Acta. 2015;438:316–22.PubMedCrossRef
130.
Horowitz MC, Bothwell AL, Hesslein DG, Pflugh DL, Schatz DG. B cells and osteoblast and osteoclast development. Immunol Rev. 2005;208:141–53.PubMedCrossRef
131.
Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A. 1993;90:11924–8.PubMedPubMedCentralCrossRef
132.
Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone. 1999;25:255–9.PubMedCrossRef
133.
Zaiss MM, Axmann R, Zwerina J, Polzer K, Gückel E, Skapenko A, et al. Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum. 2007;56:4104–12.PubMedCrossRef
134.
Ma L, Makino Y, Yamaza H, Akiyama K, Hoshino Y, Song G, et al. Cryopreserved dental pulp tissues of exfoliated deciduous teeth is a feasible stem cell resource for regenerative medicine. PLoS One. 2012;7:e51777.PubMedPubMedCentralCrossRef
135.
Tyagi AM, Mansoori MN, Srivastava K, Khan MP, Kureel J, Dixit M, et al. Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-α antibodies. J Bone Miner Res. 2014;29:1981–92.PubMedCrossRef
136.
Gonçalves-Zillo TO, Pugliese LS, Sales VM, Mori MA, Squaiella-Baptistão CC, Longo-Maugéri IM, et al. Increased bone loss and amount of osteoclasts in kinin B1 receptor knockout mice. J Clin Periodontol. 2013;40:653–60.PubMedCrossRef
137.
Yap KS, Morand EF. Vitamin D and systemic lupus erythematosus: continued evolution. Int J Rheum Dis. 2015;18:242–9.PubMedCrossRef
138.
Sioka C, Kyritsis AP, Fotopoulos A. Multiple sclerosis, osteoporosis, and vitamin D. J Neurol Sci. 2009;287:1–6.PubMedCrossRef
139.
Olsson A, Oturai DB, Sørensen PS, Oturai PS, Oturai AB. Short-term, high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis. Mult Scler. 2015;21:1557–65.PubMedCrossRef
140.
Forrest KY, Stuhldreher WL. Prevalence and correlates of vitamin D deficiency in US adults. Nutr Res. 2011;31:48–54.PubMedCrossRef
141.
Grethen E, McClintock R, Gupta CE, Jones R, Cacucci BM, Diaz D, et al. Vitamin D and hyperparathyroidism in obesity. J Clin Endocrinol Metab. 2011;96:1320–6.PubMedPubMedCentralCrossRef
142.
Vimaleswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT, et al. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med. 2013;19:951–60.
143.
144.
Marcotorchino J, Tourniaire F, Astier J, Karkeni E, Canault M, Amiot MJ, et al. Vitamin D protects against diet-induced obesity by enhancing fatty acid oxidation. J Nutr Biochem. 2014;25:1077–83.PubMedCrossRef
145.
Fini M, Giavaresi G, Salamanna F, Veronesi F, Martini L, De Mattei M, et al. Harmful lifestyles on orthopedic implantation surgery: a descriptive review on alcohol and tobacco use. J Bone Miner Metab. 2011;29:633–44.PubMedCrossRef
146.
Zhao LJ, Jiang H, Papasian CJ, Maulik D, Drees B, Hamilton J, et al. Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. J Bone Miner Res. 2008;1:17–29.
147.
148.
Williams FM, Spector TD. Recent advances in the genetics of osteoporosis. Musculoskelet Neuronal Interact. 2006;6:27–35.
149.
Ji GR, Yao M, Sun CY, Li ZH, Han Z. BsmI, TaqI, ApaI and FokI polymorphisms in the vitamin D receptor (VDR) gene and risk of fracture in Caucasians: a meta-analysis. Bone. 2010;47:681–6.PubMedCrossRef
150.
Deng H, Liu F, Pan Y, Jin X, Wang H, Cao J. BsmI, TaqI, ApaI, and FokI polymorphisms in the vitamin D receptor gene and periodontitis: a meta-analysis of 15 studies including 1338 cases and 1302 controls. J Clin Periodontol. 2011;38:199–207.PubMedCrossRef
151.
Li Y, Xi B, Li K, Wang C. Association between vitamin D receptor gene polymorphisms and bone mineral density in Chinese women. Mol Biol Rep. 2012;39:5709–17.PubMedCrossRef
152.
Marozik P, Mosse I, Alekna V, Rudenko E, Tamulaitienė M, Ramanau H, et al. Association between polymorphisms of VDR, COL1A1, and LCT genes and bone mineral density in Belarusian women with severe postmenopausal osteoporosis. Medicina (Kaunas). 2013;49:177–84.
153.
Tarner IH, Erkal MZ, Obermayer-Pietsch BM, Hofbauer LC, Bergmann S, Goettsch C, et al. Osteometabolic and osteogenetic pattern of Turkish immigrants in Germany. Exp Clin Endocrinol Diabetes. 2012;120:517–23.PubMedCrossRef
154.
Kurt O, Yilmaz-Aydogan H, Uyar M, Isbir T, Seyhan MF, Can A. Evaluation of ERα and VDR gene polymorphisms in relation to bone mineral density in Turkish postmenopausal women. Mol Biol Rep. 2012;39:6723–30.PubMedCrossRef
155.
Pouresmaeili F, Jamshidi J, Azargashb E, Samangouee S. Association between vitamin D receptor gene BsmI polymorphism and bone mineral density in a population of 146 Iranian women. Cell J. 2013;15:75–82.PubMedPubMedCentral
156.
Khatkhatay MI. Genetic factors contributing to osteoporosis: study of vitamin D receptor polymorphism and estrogen receptor gene in Indian population. Hum Mol Genet. 2004;13:1633–9.CrossRef
157.
Thakkinstian A, Eisman J, Atteia J, Neygyen J. Meta-analysis of molecular association studies: vitamin D receptor gene polymorphisms and BMD as a case study. J Bone Miner Res. 2004;19:419–28.PubMedCrossRef
158.
Horst-Sikorska W, Ignaszak-Szczepaniak M, Marcinkowska M, Kaczmarek M, Stajgis M, Slomski R. Association analysis of vitamin D receptor gene polymorphisms with bone mineral density in young women with Graves’ disease. Acta Biochim Pol. 2008;55:371–80.PubMed
159.
Creatsa M, Pliatsika P, Kaparos G, Antoniou A, Armeni E, Tsakonas E, et al. The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study. J Obstet Gynaecol Res. 2011;37:1415–22.PubMedCrossRef
160.
Lisker R, López MA, Jasqui S, Ponce De León Rosales S, Correa-Rotter R, Sánchez S, et al. Association of vitamin D receptor polymorphisms with osteoporosis in Mexican postmenopausal women. Hum Biol. 2003;75:399–403.PubMedCrossRef
161.
Kiel DP, Demissie S, Dupuis J, Lunetta KL, Murabito JM, Karasik D. Genome-wide association with bone mass and geometry in the Framingham Heart Study. BMC Med Genet. 2007;19:S14.CrossRef
162.
Mosaad YM, Hammadb EM, Fawzy Z, Abdal IA, Youssef HM, ElSaid TO, et al. Vitamin D receptor gene polymorphism as possible risk factor in rheumatoid arthritis and rheumatoid related osteoporosis. Hum Immunol. 2014;75:452–61.PubMedCrossRef
163.
Hussien YM, Shehata A, Karam RA, Alzahrani SS, Magdy H, El-Shafey AM. Polymorphism in vitamin D receptor and osteoprotegerin genes in Egyptian rheumatoid arthritis patients with and without osteoporosis. Mol Biol Rep. 2013;40:3675–80.PubMedCrossRef
164.
Jia F, Sun RF, Li QH, Wang DX, Zhao F, Li JM, et al. Vitamin D receptor BsmI polymorphism and osteoporosis risk: a meta-analysis from 26 studies. Genet Test Mol Biomarkers. 2013;17:30–4.PubMedCrossRef
165.
Qin G, Dong Z, Zeng P, Liu M, Liao X. Association of vitamin D receptor BsmI gene polymorphism with risk of osteoporosis: a meta-analysis of 41 studies. Mol Biol Rep. 2013;40:497–506.PubMedCrossRef
166.
Shen H, Xie J, Lu H. Vitamin D receptor gene and risk of fracture in postmenopausal women: a meta-analysis. Climacteric. 2014;17:319–24.PubMedCrossRef
167.
Wu FY, Liu CS, Liao LN, Li CI, Lin CH, Yang CW, et al. Vitamin D receptor variability and physical activity are jointly associated with low handgrip strength and osteoporosis in community-dwelling elderly people in Taiwan: the Taichung Community Health Study for Elders (TCHS-E). Osteoporos Int. 2014;25:1917–29.PubMedCrossRef
168.
Lauridsen AL, Vestergaard P, Nexo E. Mean serum concentration of vitamin D-binding protein (Gc globulin) is related to the Gc phenotype in women. Clin Chem. 2001;47:753–6.PubMed
169.
Lauridsen AL, Vestergaard P, Hermann AP, Moller HJ, Mosekilde L, Nexo E. Female premenopausal fracture risk is associated with Gc phenotype. J Bone Miner Res. 2004;19:875–81.PubMedCrossRef
170.
Lauridsen AL, Vestergaard P, Hermann AP, Brot C, Heickendorff L, Mosekilde L, et al. Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int. 2005;77:15–22.PubMedCrossRef
171.
Pekkinen M, Saarnio E, Viljakainen HT, Kokkonen E, Jakobsen J, Cashman K, et al. Vitamin D binding protein genotype is associated with serum 25-hydroxyvitamin D and PTH concentrations, as well as bone health in children and adolescents in Finland. PLoS One. 2014;9:e87292.PubMedPubMedCentralCrossRef
172.
Xu XH, Xiong DH, Liu XG, Guo Y, Chen Y, Zhao J, et al. Association analyses of vitamin D-binding protein gene with compression strength index variation in Caucasian nuclear families. Osteoporos Int. 2010;21:99–107.PubMedCrossRef
173.
Taes YE, Goemaere S, Huang G, Van Pottelbergh I, De Bacquer D, Verhasselt B, et al. Vitamin D binding protein, bone status and body composition in community-dwelling elderly men. Bone. 2006;38:701–7.PubMedCrossRef
174.
Al-oanzi ZH, Tuck SP, Mastana SS, Summers GD, Cook DB, Francis RM, et al. Vitamin D binding protein gene microsatellite polymorphism influences BMD and risk of fractures in men. Osteoporos Int. 2008;19:951–60.PubMedCrossRef
175.
Papiha SS, Allcroft LC, Kanan RM, Francis RM, Datta HK. Vitamin D binding protein gene in male osteoporosis: association of plasma DBP and bone mineral density with (TAAA)n-Alu polymorphism in DBP. Calcif Tissue Int. 1999;65:262–6.PubMedCrossRef
176.
Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta. 2006;372:33–42.PubMedCrossRef
177.
Thongthai P, Chailurkit LO, Chanprasertyothin S, Nimitphong H, Sritara P, Aekplakorn W, et al. Vitamin D binding protein gene polymorphism as a risk factor for vitamin D deficiency in Thais. Endocr Pract. 2015;21:221–5.PubMedCrossRef
178.
Ezura Y, Nakajima T, Kajita M, Ishida R, Inoue S, Yoshida H, et al. Association of molecular variants, haplotypes, and linkage disequilibrium within the human vitamin D-binding protein (DBP) gene with postmenopausal bone mineral density. J Bone Miner Res. 2003;18:1642–9.PubMedCrossRef
179.
Sinotte M, Diorio C, Bérubé S, Pollak M, Brisson J. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr. 2009;89:634–40.PubMedCrossRef
180.
Bu FX, Armas L, Lappe J, Zhou Y, Gao G, Wang HW, et al. Comprehensive association analysis of nine candidate genes with serum 25-hydroxy vitamin D levels among healthy Caucasian subjects. Hum Genet. 2010;128:549–56.PubMedCrossRef
181.
Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A. 2004;101:7711–5.PubMedPubMedCentralCrossRef
182.
Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet. 2010;19:2739–45.PubMedPubMedCentralCrossRef
183.
Ramos-Lopez E, Kahles H, Weber S, Kukic A, Penna-Martinez M, Badenhoop K, et al. Gestational diabetes mellitus and vitamin D deficiency: genetic contribution of CYP27B1 and CYP2R1 polymorphisms. Diabetes Obes Metab. 2008;10:683–5.PubMedCrossRef
184.
Massey K, Dickerson RN, Brown RO. A review of vitamin D deficiency in the critical care population. Pharmacy. 2014;2:40–9.CrossRef
Metadata
Title
Vitamin D Level Between Calcium-Phosphorus Homeostasis and Immune System: New Perspective in Osteoporosis
Authors
Daniele Bellavia
Viviana Costa
Angela De Luca
Melania Maglio
Stefania Pagani
Milena Fini
Gianluca Giavaresi
Publication date
13-10-2016
Publisher
Springer US
Published in
Current Osteoporosis Reports
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-016-0331-2